Docetaxel Labeled with Iodine 131 Radionuclide – A Possible New Anticancer Drug? (The Pilot Study)

Pastera, Jiří; Rudolf, Emil; Dittrich, Milan

doi:10.14712/18059694.2017.130

Acta Medica > Archive > 2006, Vol. 49 > Issue 3 > Docetaxel Labeled with Iodine 131…

Acta Med. 2006, 49: 189-192

https://doi.org/10.14712/18059694.2017.130

Docetaxel Labeled with Iodine 131 Radionuclide – A Possible New Anticancer Drug? (The Pilot Study)

Jiří Pastera^a, Emil Rudolf^b, Milan Dittrich^c

^aInstitute of Experimental Biopharmaceutics, Joint Research Center of Czech Academy of Sciences and PRO.MED.CS Praha, Hradec Králové, Czech Republic
^bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Hradec Králové, Czech Republic
^cCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmaceutical Technology, Hradec Králové, Czech Republic

Received July 1, 2006
Accepted September 1, 2006

The cytotoxic potentials of the lipiodol emulsion with dissolved ¹³¹I-docetaxel, the ¹³¹I-lipiodol emulsion and non-labeled docetaxel were tested on the HeLa Hep2 cell line during 24 hours. The pilot study confirmed that the radiolabeled docetaxel was significantly more toxic than the radionuclide or docetaxel alone.

Keywords

In vitro, Taxanes, Lipiodol, Docetaxel, 131–iodine, Cytotoxicity.

Funding

The project of the biodistribution of the ¹³¹I-lipiodol and ¹³¹I-docetaxel and this pilot study of the cytotoxicity were 191 done with financial support from “Terry Fox Run” which was organized by Canadian Embassy in Prague (Czech Republic).